AzTrials
AzTrials

Overweight , ObesityNCT07748468

Impact of Antioxidant-rich Supplementation on Skin Carotenoids Status, Antioxidant Status and Cardiometabolic Health in Overweight and Obese Individuals

A study testing Antioxidant-rich supplementation Element and Antioxidant-rich supplementation Optimal in people with Overweight , Obesity and Antioxidant Status, run by National University of Singapore at 1 site in Singapore.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

This study aims to evaluate the effects of antioxidant-rich supplementation on skin carotenoid status, antioxidant status, and cardiometabolic health in overweight and obese individuals. Read more about this study

Who is it for?
Ages 21 to 70 yearsHealthy volunteers can take part
Conditions the study is for
Overweight , Obesity, Antioxidant Status
What is being tested?
Antioxidant-rich supplementation Element and Antioxidant-rich supplementation Optimal
Could I receive a placebo?
No, everyone receives an active treatment
How many people
83 participants
Where
1 siteSingapore
Study dates
15 Aug 2026to 31 Dec 2027
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 21 to 70 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Able to give informed consent (AMT score ≥ 8 for older adults [65-70 years old])
  • Adults 21-70 years old
  • English-literate
  • Have venous access sufficient to allow for blood sampling as per the protocol
  • No drastic change of diet for the past 1 year
  • If taking medication, has been consistently taking antihypertensive/cholesterol-lowering/type-2 diabetic medication for more than 3 years prior to starting the study

Who cannot join

  • Weight change > 3kg in the past 3 months
  • Exercising vigorously over the past 3 months
  • Taking medications or dietary supplements which may impact eye/skin health
  • Taking lipid-lowering and blood pressure controlling medications less than 3 years
  • Smoking
  • Drinking more than 2 alcoholic drinks per day
  • Pregnant, lactating, or planning pregnancy in the next 6 months

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Lingyin Yu, B.Sc. contact

(+65) 8942 1809

e1124962@u.nus.edu

Singapore1 site

  • NUS, Department of Food Science and Technology, 1 Science Drive 3, Block S13, #03-07, Singapore, 117550

    Singapore, 117542

    Lingyin Yu, B.Sc., (+65) 8942 1809, e1124962@u.nus.edu

    Jung Eun Kim, Ph.D., R.D.

Other trials in Singapore

About this study

This study aims to evaluate the effects of antioxidant-rich supplementation on skin carotenoid status, antioxidant status, and cardiometabolic health in overweight and obese individuals. The study may provide additional scientific evidence to support the further refinement of current dietary and nutritional recommendations.

Read the detailed description

This study will be a single-blind, randomized, parallel-group trial, and all participants will complete a 12-week study period. A total of 66 participants will be recruited and randomly assigned to continue their habitual diet with or without antioxidant-rich supplementation. This study aims to investigate whether antioxidant-rich supplementation will influence body composition, skin carotenoid status, antioxidant status, and cardiometabolic health. The study will comprise 1 screening visit and 4 test visits.

Being tested
Antioxidant-rich supplementation Element, Antioxidant-rich supplementation Optimal
Keywords
Overweight, Obese, Antioxidants, Long-term, Body composition, Cardiometabolic health, Skin carotenoid
Medical subject headings
Overweight, Obesity

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Antioxidant-rich supplementation ElementDietary supplement

    Maintained habitual diet with additionally taking LifePak Element for 12 weeks

  • Antioxidant-rich supplementation OptimalDietary supplement

    Maintaining habitual diet with additionally taking LifePak Optimal for 12 weeks

Study groups in NCT07748468
Study groupRoleWhat they receive
ControlNo interventionMaintained habitual diet without receving the intervention.
LifePak Elements SupplementationExperimentalConsume the LifePak (Elements) every day for 12 weeks.
Receives: Dietary Supplement: Antioxidant-rich supplementation Element
LifePak Optimal SupplementationExperimentalConsume the LifePak (Optimal) every day for 12 weeks.
Receives: Dietary Supplement: Antioxidant-rich supplementation Optimal

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in Skin Carotenoid Score Measured by Prysm iO™ from Baseline to Week 12

    Skin carotenoid status will be assessed using the Prysm iO™ device. The device scans the participant's fingertip and provides a skin carotenoid score, also referred to as the Prysm Score. Results will be reported as the numerical Prysm Score. Higher scores indicate higher skin carotenoid levels.

    Measured: Week 0, 4, 8, 12

  2. Mean Change from Baseline in Blood Carotenoid Concentration

    Blood carotenoid concentration will be assessed using blood samples collected from participants. Results will be reported as the mean change from baseline in blood carotenoid concentration at Week 12. Higher concentrations indicate higher circulating carotenoid status.

    Measured: Week 0 and Week 12

Secondary outcomes (8)

  1. Mean Change from Baseline in Total Antioxidant Capacity in Blood Samples

    Total antioxidant capacity will be assessed using blood samples collected from participants. Results will be reported as the mean change from baseline in total antioxidant capacity at each post-baseline time point.

    Measured: Week 0 and Week 12

  2. Mean Change from Baseline in Fasting Blood Lipid and Lipoprotein Concentrations

    Fasting blood lipid and lipoprotein concentrations will be assessed using blood samples collected from participants after an overnight fast. The lipid and lipoprotein profile may include total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and triglycerides. Results will be reported as the mean change from baseline in each lipid and lipoprotein parameter at Week 12.

    Measured: Week 0 and Week 12

  3. Mean Change from Baseline in Fasting Blood Glucose Concentration

    Fasting blood glucose concentration will be assessed using blood samples collected from participants after an overnight fast. Results will be reported as the mean change from baseline in fasting blood glucose concentration at Week 12.

    Measured: Week 0 and Week 12

  4. Mean Change from Baseline in Fasting Blood Insulin Concentration

    Fasting blood insulin concentration will be assessed using blood samples collected from participants after an overnight fast. Results will be reported as the mean change from baseline in fasting blood insulin concentration at Week 12.

    Measured: Week 0 and Week 12

  5. Mean Change from Baseline in Blood Biomarkers of Oxidative Stress: Malondialdehyde and 8-Isoprostane

    Oxidative stress will be assessed using blood samples collected from participants. Blood biomarkers of oxidative stress will include malondialdehyde and 8-isoprostane. Results will be reported as the mean change from baseline in malondialdehyde concentration and 8-isoprostane concentration at Week 12. Higher concentrations indicate higher levels of oxidative stress.

    Measured: Week 0 and Week 12

  6. Mean Change from Baseline in Skin Autofluorescence Measured by AGE Reader mu Connect

    Skin advanced glycation end product accumulation will be assessed non-invasively using the AGE Reader mu Connect. The device measures skin tissue autofluorescence on the inside of the participant's dominant lower forearm. Results will be reported as the mean change from baseline in AGE Reader measurement result, expressed in arbitrary units. Higher values indicate higher skin advanced glycation end product accumulation.

    Measured: Week 0, 4, 8, 12

  7. Mean Change from Baseline in Blood Advanced Glycation End Product Level

    Blood advanced glycation end product level will be assessed using blood samples collected from participants. Results will be reported as the mean change from baseline in blood advanced glycation end product level at Week 12.

    Measured: Week 0 and Week 12

  8. Mean change from baseline in anthropometric and body composition parameters

    Anthropometric and body composition parameters will be assessed using standard measurements and InBody body composition analysis. Parameters may include body weight, waist circumference, body fat percentage, fat mass, fat-free mass, skeletal muscle mass and body mass index. Results will be reported as the mean change from baseline at each post-baseline time point.

    Measured: Week 0, 4, 8, 12

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted5 Aug 2026
  2. Study start15 Aug 2026 (estimated)
  3. Primary completion1 Aug 2027 (estimated)
  4. Study completion31 Dec 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Investigator, Outcomes assessor
Enrolment
83 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07748468
Sponsor's protocol ID
S39
Other IDs
NUS-IRB-2026-268
Status last verified
Mar 2026
First submitted
15 May 2026
Last updated
5 Aug 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: Electronic copies of the data with identifiable participant information will be kept on NUS OneDrive with access limited only Dr Kim Jung Eun and her research staff. All data will be de-identified prior to statistical analyses.

Questions about this trial

What is this clinical trial studying?

A study testing Antioxidant-rich supplementation Element and Antioxidant-rich supplementation Optimal in people with Overweight , Obesity and Antioxidant Status, run by National University of Singapore at 1 site in Singapore.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 5 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Singapore. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Lingyin Yu, B.Sc. ((+65) 8942 1809, e1124962@u.nus.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in Skin Carotenoid Score Measured by Prysm iO™ from Baseline to Week 12 (time frame: Week 0, 4, 8, 12). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07748468.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Aug 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in